FP
CTMX icon

Foundry Partners’s CytomX Therapeutics CTMX Stock Holding History

Foundry Partners’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-39,862
Closed -$737K – 391
2018
Q3 		$737K Sell
39,862
-62
-0.2% -$1.41K 0.03% 338
2018
Q2 		$913K Sell
39,924
-2,578
-6% -$65.8K 0.04% 323
2018
Q1 		$1.21M Sell
42,502
-98
-0.2% -$2.8K 0.05% 315
2017
Q4 		$899K Sell
42,600
-33,675
-44% -$698K 0.04% 320
2017
Q3 		$1.39M Sell
76,275
-223
-0.3% -$3.48K 0.06% 313
2017
Q2 		$1.19M Buy
+76,498
New +$1.15M 0.05% 325

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Foundry Partners's CTMX Position: Q4 2018 in Review

Foundry Partners sold out of CytomX Therapeutics (CTMX) in Q4 2018, closing a stake of 39,862 shares — an estimated $737K sold.

Foundry Partners first reported a position in CTMX in Q2 2017 and held it in 6 quarters. The position peaked at $1.39M in Q3 2017. 111 funds tracked by Wall St. Rank hold CTMX as of Q4 2018.

  • Foundry Partners reported no remaining CytomX Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Foundry Partners sold 39,862 CytomX Therapeutics shares in Q4 2018, an estimated $737K.
  • Foundry Partners first reported a position in CytomX Therapeutics in Q2 2017 and held it in 6 quarters.
  • Foundry Partners's CytomX Therapeutics position peaked at $1.39M in Q3 2017.
  • 111 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2018.

Based on Foundry Partners's 13F filing for Q4 2018, filed 10 Jan 2019.